Skip to main content
. 2019 Jan 29;9(2):13. doi: 10.1038/s41408-019-0174-z

Table 2.

Clinical characteristics and prognostic factors

Patient number, n 214
Age, years 60 (37–70)
Gender, n (%)
 Male 129 (60.3)
 Female 85 (39.7)
Heavy chain type, n (%)
 IgG 136 (63.6)
 IgA 30 (14.0)
 Other (IgM, IgD, and IgE) 4 (1.9)
 None 44 (20.6)
Light chain type, n (%)
 κ 146 (68.2)
 λ 68 (31.8)
β2-microglobulin (mg/l) 3.4 (1.0–17.4)
Albumin (g/l) 37 (20.0–56.0)
ISS, n (%)
 I 80 (37.4)
 II 81 (37.9)
 III 53 (24.8)
Cytogenetic risk groupa, n (%)
 Standard risk 155 (79.5)
 High risk 40 (20.5)
 Missing 19
Cytogenetic risk groupb, n (%)
 Standard risk 149 (76.4)
 High risk 46 (23.6)
 Missing 19
Immonophenotypic prognostic markers, n (%)
 CD27-positive 196 (96.5)
 CD27-negative 7 (3.4)
 Missing 11
 CD81-positive 140 (69.3)
 CD81-negative 62 (30.7)
 Missing 12

Unless indicated otherwise, data are presented as medians (ranges)

ISS International Staging System

aCytogenetic high-risk group: presence of del17p and/or t(4;14) or a gain at 1q of >3 copies

bCytogenetic high-risk group: presence of del17p and/or t(4;14) or t(14;16)